Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Merck"

190 News Found

EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer
Drug Approval | March 28, 2024

EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer

Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results


FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
Drug Approval | March 27, 2024

FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension

WINREVAIR is a breakthrough biologic for this rare, progressive disease


Merck invests € 300 million in new Life Science production site in South Korea
News | March 21, 2024

Merck invests € 300 million in new Life Science production site in South Korea

New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics


Merck plans to conduct clinical trials of a novel investigational HPV vaccine for GARDASIL9
Diagnostic Center | March 14, 2024

Merck plans to conduct clinical trials of a novel investigational HPV vaccine for GARDASIL9

Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers


Merck completes acquisition of Harpoon Therapeutics
News | March 12, 2024

Merck completes acquisition of Harpoon Therapeutics

Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager


Merck Animal Health to acquire Elanco’s aqua business
News | February 07, 2024

Merck Animal Health to acquire Elanco’s aqua business

Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries


Merck’s Keytruda reduced the risk of death by 38% for patients with RCC
Diagnostic Center | January 29, 2024

Merck’s Keytruda reduced the risk of death by 38% for patients with RCC

Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC


USFDA approves Merck’s Keytruda plus chemoradiotherapy with FIGO 2014 stage III-IVA cervical cancer
Drug Approval | January 13, 2024

USFDA approves Merck’s Keytruda plus chemoradiotherapy with FIGO 2014 stage III-IVA cervical cancer

Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients


Merck to acquire Harpoon Therapeutics for US$ 680 million
News | January 10, 2024

Merck to acquire Harpoon Therapeutics for US$ 680 million

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors


Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline
Diagnostic Center | January 06, 2024

Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline

Comprehensive clinical development programs being initiated for each investigational candidate